FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3015544113> ?p ?o ?g. }

• W3015544113 endingPage "1448" @default.
• W3015544113 startingPage "1448" @default.
• W3015544113 abstract "1448 Introduction: Prostate cancer is the most common solid malignancy in men and the third leading cause of cancer related death in the United States. Prostate-specific membrane antigen (PSMA) is a type II transmembrane protein that acts as a glutamate carboxypeptidase enzyme. Its9 high expression in prostate cancer cells makes it a useful target for diagnostic and therapeutic applications in nuclear medicine. One of the most common indications for Ga68 PSMA PET/CT is biochemical failure in castrate resistant prostate cancer (CRPC). Recent studies aimed to investigate the value of Ga68 PSMA PET/CT in patients (pts) with biochemical failure have shown a detection rate of up to 97% with good correlation to PSA levels and PSA velocity. The aim of the study was to investigate the characteristics of CRPC pts with biochemical failure and negative Ga68-PSMA in comparison to those with positive studies. Materials and methods: All Ga68-PSMA studies performed for the indication of CRPC with biochemical failure in two academic centers over a period of 24 months were retrospectively reviewed. Clinical, laboratory and imaging data including: demographic data, Gleason score at diagnosis, PSA levels and treatment history, were collected and analyzed. The different characteristics of pts with negative Ga68 PSMA PET/CT were compared to those with positive studies. Differences between groups were analyzed using student t-test, p<0.05 was considered statistically significant. Results: Two hundred and seventy studies were performed in 266 prostate cancer pts with biochemical failure. There were 181 (67%) positive studies (in 178 pts) and 89 (33%) studies in 88 pts were negative. The mean age of the pts with positive studies was 65.7 years (48-82y) and of those with negative studies was 62.8 years (48-79y). The mean Gleason score at diagnosis was 7.5 (5-10) for the positive studies and 7 (6-9) for the negative group (p=0.006).The average PSA level at the time of the study was 20.5 ng/mL (0.12-416 ng/mL) in the positive group and 3.6 ng/mL (0.02-75 ng/mL) in pts with negative PET/CT results (p=0.002). The treatment history of the PET/CT positive group included radical prostatectomy in 65 pts (37%), hormonal therapy (109 pts, 60%), local radiotherapy (109 pts, 60%) and other treatments (including brachytherapy, radiotherapy to other body parts apart from the pelvis, therapy with radioactive drugs and chemotherapy) in 31 pts (17%). Fifty-three (60%) of the pts with negative PET/CT studies underwent radical prostatectomy, 33 (37%) received hormonal therapy, 42 (48%) had radiotherapy to the pelvis and 4 (4%) had brachytherapy. Previous radical prostatectomy was more prevalent in pts with negative studies in comparison to those with positive results (60% vs. 37%) (p=0.0025). Overall, pts with positive studies underwent more treatment regimens per patient in comparison to the group of pts with negative PET/CT results (1.76 vs. 1.48) (p=0.034). Conclusions: Ga68-PSMA PET/CT was negative in one third of CRPC pts with biochemical failure. Positive studies were associated with greater Gleason scores at diagnosis and higher PSA values. Previous radical prostatectomy was more common in pts with biochemical failure and negative studies , however, pts with positive studies underwent more treatment regimens in comparison to pts with negative PET/CT studies." @default.
• W3015544113 created "2020-04-17" @default.
• W3015544113 creator A5006748646 @default.
• W3015544113 creator A5023547493 @default.
• W3015544113 creator A5026232049 @default.
• W3015544113 creator A5058714044 @default.
• W3015544113 creator A5075627465 @default.
• W3015544113 creator A5080058125 @default.
• W3015544113 date "2018-05-01" @default.
• W3015544113 modified "2023-09-24" @default.
• W3015544113 title "Positive and Negative Ga68-PSMA PET/CT Studies in Prostate Cancer Patients with Biochemical Failure - Comparison of Patients' Characteristics" @default.
• W3015544113 hasPublicationYear "2018" @default.
• W3015544113 type Work @default.
• W3015544113 sameAs 3015544113 @default.
• W3015544113 citedByCount "0" @default.
• W3015544113 crossrefType "journal-article" @default.
• W3015544113 hasAuthorship W3015544113A5006748646 @default.
• W3015544113 hasAuthorship W3015544113A5023547493 @default.
• W3015544113 hasAuthorship W3015544113A5026232049 @default.
• W3015544113 hasAuthorship W3015544113A5058714044 @default.
• W3015544113 hasAuthorship W3015544113A5075627465 @default.
• W3015544113 hasAuthorship W3015544113A5080058125 @default.
• W3015544113 hasConcept C121608353 @default.
• W3015544113 hasConcept C126322002 @default.
• W3015544113 hasConcept C143998085 @default.
• W3015544113 hasConcept C20417620 @default.
• W3015544113 hasConcept C2776235491 @default.
• W3015544113 hasConcept C2779399171 @default.
• W3015544113 hasConcept C2780192828 @default.
• W3015544113 hasConcept C71924100 @default.
• W3015544113 hasConceptScore W3015544113C121608353 @default.
• W3015544113 hasConceptScore W3015544113C126322002 @default.
• W3015544113 hasConceptScore W3015544113C143998085 @default.
• W3015544113 hasConceptScore W3015544113C20417620 @default.
• W3015544113 hasConceptScore W3015544113C2776235491 @default.
• W3015544113 hasConceptScore W3015544113C2779399171 @default.
• W3015544113 hasConceptScore W3015544113C2780192828 @default.
• W3015544113 hasConceptScore W3015544113C71924100 @default.
• W3015544113 hasLocation W30155441131 @default.
• W3015544113 hasOpenAccess W3015544113 @default.
• W3015544113 hasPrimaryLocation W30155441131 @default.
• W3015544113 hasRelatedWork W2588873924 @default.
• W3015544113 hasRelatedWork W2754546503 @default.
• W3015544113 hasRelatedWork W2883030921 @default.
• W3015544113 hasRelatedWork W2883850634 @default.
• W3015544113 hasRelatedWork W2896566817 @default.
• W3015544113 hasRelatedWork W2896905478 @default.
• W3015544113 hasRelatedWork W2898441448 @default.
• W3015544113 hasRelatedWork W2917217930 @default.
• W3015544113 hasRelatedWork W2966792020 @default.
• W3015544113 hasRelatedWork W2967355800 @default.
• W3015544113 hasRelatedWork W2981395014 @default.
• W3015544113 hasRelatedWork W2987171095 @default.
• W3015544113 hasRelatedWork W2996649940 @default.
• W3015544113 hasRelatedWork W3006239597 @default.
• W3015544113 hasRelatedWork W3009522086 @default.
• W3015544113 hasRelatedWork W3085058955 @default.
• W3015544113 hasRelatedWork W3138949375 @default.
• W3015544113 hasRelatedWork W3166265810 @default.
• W3015544113 hasRelatedWork W3185994703 @default.
• W3015544113 hasRelatedWork W616430046 @default.
• W3015544113 hasVolume "59" @default.
• W3015544113 isParatext "false" @default.
• W3015544113 isRetracted "false" @default.
• W3015544113 magId "3015544113" @default.
• W3015544113 workType "article" @default.